Financial reports
10-Q
2024 Q1
Quarterly report
25 Apr 24
ARS
2023 FY
Annual report to shareholders
23 Apr 24
10-K
2023 FY
Annual report
28 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
1 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
2 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
Current reports
8-K
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
23 Apr 24
8-K
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
2 Apr 24
8-K
Practice Statement Letter
29 Mar 24
8-K
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
28 Feb 24
8-K
Kiniksa Pharmaceuticals Provides Corporate Update
4 Jan 24
8-K
Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution
31 Oct 23
8-K
Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution
25 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
7 Jun 23
8-K
Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution
2 May 23
8-K
Regulation FD Disclosure
10 Mar 23
Registration and prospectus
S-8
Registration of securities for employees
28 Feb 24
S-8
Registration of securities for employees
2 Mar 23
S-3
Shelf registration
6 May 22
S-3
Shelf registration
6 May 22
S-8
Registration of securities for employees
24 Feb 22
S-8
Registration of securities for employees
25 Feb 21
D/A
$8.8M in equity, sold $8.8M, 10 investors
23 Nov 20
S-3
Shelf registration
8 Sep 20
424B5
Prospectus supplement for primary offering
22 Jul 20
424B5
Prospectus supplement for primary offering
20 Jul 20
Proxies
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
PRE 14A
Preliminary proxy
10 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Mar 24
DEFA14A
Additional proxy soliciting materials
29 Mar 24
DEF 14A
Definitive proxy
27 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
DEFA14A
Additional proxy soliciting materials
28 Apr 21
Other
UPLOAD
Letter from SEC
2 Jan 24
CORRESP
Correspondence with SEC
8 Dec 23
CORRESP
Correspondence with SEC
21 Nov 23
UPLOAD
Letter from SEC
16 Nov 23
EFFECT
Notice of effectiveness
18 May 22
EFFECT
Notice of effectiveness
18 May 22
UPLOAD
Letter from SEC
13 May 22
CORRESP
Correspondence with SEC
13 May 22
CORRESP
Correspondence with SEC
13 May 22
UPLOAD
Letter from SEC
13 May 22